激素治疗在前列腺癌管理中的应用：循证方法。
Hormone therapy in the management of prostate cancer: evidence-based approaches.
机构信息
Chairman, Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, 1025 Walnut Street, Suite 1112, Philadelphia, PA 19107, USA.
出版信息
Ther Adv Urol. 2010 Aug;2(4):171-81. doi: 10.1177/1756287210375270.
Abstract
Hormonal therapy has been the standard for advanced prostate cancer for over 60 years. Recently, the utility of androgen ablation through various means has been demonstrated for earlier stages of disease. In particular, the strongest evidence to date involves the use of hormonal therapy in combination with radiation therapy. In this article we review the basic concepts in hormonal ablation for prostate cancer and review the evidence-based studies that support the use of hormonal therapy in early stage prostate cancer.
摘要
激素治疗已经成为 60 多年来治疗晚期前列腺癌的标准方法。最近，通过各种手段进行雄激素阻断的方法在疾病早期阶段的应用也得到了证实。特别是，迄今为止最有力的证据涉及到联合使用激素治疗和放射治疗。在本文中，我们回顾了前列腺癌激素消融的基本概念，并回顾了支持在早期前列腺癌中使用激素治疗的基于证据的研究。
相似文献
1
Hormone therapy in the management of prostate cancer: evidence-based approaches.激素治疗在前列腺癌管理中的应用：循证方法。
Ther Adv Urol. 2010 Aug;2(4):171-81. doi: 10.1177/1756287210375270.
2
Medical therapy of prostate cancer. A review.前列腺癌的医学治疗。综述。
Minerva Urol Nefrol. 2005 Jun;57(2):71-84.
3
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
4
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.靶向转移性激素敏感型前列腺癌：化疗联合激素治疗及新的联合治疗策略
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
5
The selection of hormonal therapy in prostate cancer: who, when, and for how long?前列腺癌中激素疗法的选择：何人、何时以及使用多久？
J Natl Compr Canc Netw. 2004 May;2(3):261-8. doi: 10.6004/jnccn.2004.0023.
6
Endocrine treatment of prostate cancer.前列腺癌的内分泌治疗
J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31.
7
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.醋酸阿比特龙联合雄激素剥夺疗法对比单独雄激素剥夺疗法用于转移性激素敏感性前列腺癌。
Cochrane Database Syst Rev. 2020 Dec 12;12(12):CD013245. doi: 10.1002/14651858.CD013245.pub2.
8
Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.一项3期随机试验，评估二线激素治疗与多西他赛-雌莫司汀联合化疗对前列腺癌激素治疗后前列腺特异性抗原水平升高的无症状患者无进展生存期的影响：东部肿瘤协作组（E1899）、跨组/临床试验支持单位研究。
Urology. 2003 Dec 29;62 Suppl 1:141-6. doi: 10.1016/j.urology.2003.09.006.
9
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.针对未经激素治疗及去势抵抗性前列腺癌（无论是否接受过化疗）的激素疗法进展。
Exp Hematol Oncol. 2016 Jun 22;5:15. doi: 10.1186/s40164-016-0046-1. eCollection 2015.
10
Recent advances in hormonal therapy for advanced prostate cancer.晚期前列腺癌激素治疗的最新进展
Oncology (Williston Park). 2003 Aug;17(8):1047-52; discussion 1054-8.
引用本文的文献
1
Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort.在“我们所有人”研究项目队列的前列腺癌患者中，激素治疗的使用与不良心血管事件相关。
Prostate. 2025 Sep;85(12):1077-1086. doi: 10.1002/pros.24913. Epub 2025 Jun 11.
2
Exercise May Improve Completion of Standard and Emerging Cancer Treatments.运动可能会提高标准癌症治疗和新型癌症治疗的完成率。
Exerc Sport Sci Rev. 2025 Jul 1;53(3):110-124. doi: 10.1249/JES.0000000000000360. Epub 2025 Feb 18.
3
Breaking the silence: The role of extracellular vesicles in unraveling the diagnosis and treatment of endometriosis.打破沉默：细胞外囊泡在揭示子宫内膜异位症诊断与治疗中的作用
Extracell Vesicles Circ Nucl Acids. 2023 Dec 4;4(4):599-614. doi: 10.20517/evcna.2023.43. eCollection 2023.
4
The multifaceted role of extracellular vesicles in prostate cancer-a review.细胞外囊泡在前列腺癌中的多方面作用——综述
Cancer Drug Resist. 2023 Jul 28;6(3):481-498. doi: 10.20517/cdr.2023.17. eCollection 2023.
5
Correlation Between Serum Prostate-Specific Antigen and Testosterone Following Bilateral Total Orchidectomy for Patients with Advanced Prostate Cancer in Jos, Nigeria.尼日利亚乔斯晚期前列腺癌患者双侧全睾丸切除术后血清前列腺特异性抗原与睾酮的相关性
J West Afr Coll Surg. 2023 Apr-Jun;13(2):82-89. doi: 10.4103/jwas.jwas_274_22. Epub 2023 Mar 20.
6
Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics.基于进化动力学的转移性去势抵抗性前列腺癌的阿比特龙-多西他赛方案。
PLoS One. 2023 Mar 9;18(3):e0282646. doi: 10.1371/journal.pone.0282646. eCollection 2023.
7
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.我们需要了解前列腺癌中 PD-L1 表达的哪些信息？系统文献回顾。第 3 部分：PD-L1、细胞内信号通路和肿瘤微环境。
Int J Mol Sci. 2021 Nov 15;22(22):12330. doi: 10.3390/ijms222212330.
8
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).我们需要了解前列腺癌中 PD-L1 表达的哪些信息？系统文献回顾。第 4 部分：临床前研究中的实验治疗（细胞系和小鼠模型）。
Int J Mol Sci. 2021 Nov 14;22(22):12297. doi: 10.3390/ijms222212297.
9
TLX, an Orphan Nuclear Receptor With Emerging Roles in Physiology and Disease.TLX，一种孤儿核受体，在生理学和疾病中具有新兴作用。
Endocrinology. 2021 Nov 1;162(11). doi: 10.1210/endocr/bqab184.
10
Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China.高危局限性和局部晚期前列腺癌根治性前列腺切除术后的辅助激素治疗：中国首个多中心观察性研究
Chin J Cancer Res. 2019 Jun;31(3):511-520. doi: 10.21147/j.issn.1000-9604.2019.03.13.
本文引用的文献
1
Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.雄激素剥夺疗法和雌激素缺乏引起的不良反应在前列腺癌治疗中的作用。
Prostate Cancer Prostatic Dis. 2009;12(4):333-8. doi: 10.1038/pcan.2009.35. Epub 2009 Sep 1.
2
Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.全盆腔放疗联合新辅助雄激素剥夺治疗高危前列腺癌的益处。
J Biomed Biotechnol. 2009;2009:625394. doi: 10.1155/2009/625394. Epub 2009 Oct 22.
3
Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.间歇性雄激素抑制疗法治疗前列腺癌的潜在益处：文献系统评价。
Eur Urol. 2010 Jan;57(1):49-59. doi: 10.1016/j.eururo.2009.07.049. Epub 2009 Aug 7.
4
Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.根治性前列腺切除术前行 3 个月新辅助激素治疗的长期随访：一项随机试验。
BJU Int. 2010 Jan;105(2):185-90. doi: 10.1111/j.1464-410X.2009.08698.x. Epub 2009 Jul 8.
5
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.比卡鲁胺联合雄激素阻断治疗晚期前列腺癌：一项关于生存情况的3期双盲随机研究的长期随访
Cancer. 2009 Aug 1;115(15):3437-45. doi: 10.1002/cncr.24395.
6
Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy.新辅助雄激素剥夺治疗前列腺体积缩小：前列腺癌放疗中的最佳持续时间。
Urol Oncol. 2011 Jan-Feb;29(1):52-7. doi: 10.1016/j.urolonc.2009.03.024. Epub 2009 Jun 12.
7
Duration of androgen suppression in the treatment of prostate cancer.雄激素抑制在前列腺癌治疗中的持续时间。
N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.
8
Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials.局限性和局部晚期前列腺癌的辅助激素治疗：随机试验的系统评价和荟萃分析
Cancer Treat Rev. 2009 Nov;35(7):540-6. doi: 10.1016/j.ctrv.2009.05.001. Epub 2009 Jun 2.
9
Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.雄激素剥夺治疗期间的心血管和代谢并发症：运动作为一种潜在的应对措施。
Prostate Cancer Prostatic Dis. 2009;12(3):233-40. doi: 10.1038/pcan.2009.12. Epub 2009 Jun 2.
10
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.间歇性雄激素剥夺疗法治疗局部晚期和转移性前列腺癌：来自南欧泌尿肿瘤学组的一项随机3期研究结果
Eur Urol. 2009 Jun;55(6):1269-77. doi: 10.1016/j.eururo.2009.02.016. Epub 2009 Feb 21.
Zotero 插件